ArticleCancer immunology research2022
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.
Article in Cancer immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 52 citations in OpenAlex.
- Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial.Frontiers in immunology · 2024Trial
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum.Science advances · 2026Article
- FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models.Nature biotechnology · 2026Article
- Feeder-free generation of functional dendritic cells from human pluripotent stem cells.Journal for immunotherapy of cancer · 2026Article
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1.NPJ vaccines · 2026Article
- Rewiring Dendritic Cell Immunity: The β-Catenin-TIM-3 Axis as a Target to Improve DC Cancer Vaccines.Cancers · 2026Review
- Dendritic cells: the central partner for cancer immunity.Oncoimmunology · 2025Review
- Review
- Preconditioning with Low-Dose Radiation Improves Antitumor Immunity and Survival in DC-Vaccinated Mice.Life (Basel, Switzerland) · 2025Article
- PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression.Journal of pharmaceutical analysis · 2025Article
- Balancing Immunity: GSK-3's Divergent Roles in Dendritic Cell-Mediated T-Cell Priming and Memory Responses.International journal of molecular sciences · 2025Review
- Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems.Journal of nanobiotechnology · 2025Article
- IRF8 aggravates nonalcoholic fatty liver disease via BMAL1/PPARγ axis.Genes & diseases · 2025Article
- Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse.Nature communications · 2025Article
- Cross-priming in cancer immunology and immunotherapy.Nature reviews. Cancer · 2025Review
- Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer.Molecular cancer therapeutics · 2025Article
- Lipid Nanoparticle-mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response.Small methods · 2025Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
As a cell-based cancer vaccine, dendritic cells (DC), derived from peripheral blood monocytes or bone marrow (BM) treated with GM-CSF (GMDC), were initially thought to induce antitumor immunity by presenting tumor antigens directly to host T cells. Subsequent work revealed that GMDCs do not directly prime tumor-specific T cells, but must transfer their antigens to host DCs. This reduces their advantage over strictly antigen-based strategies proposed as cancer vaccines. Type 1 conventional DCs (cDC1) have been reported to be superior to GMDCs as a cancer vaccine, but whether they act by transferring antigens to host DCs is unknown. To test this, we compared antitumor responses induced by GMDCs and cDC1 in Irf8 +32-/- mice, which lack endogenous cDC1 and cannot reject immunogenic fibrosarcomas. Both GMDCs and cDC1 could cross-present cell-associated antigens to CD8+ T cells in vitro. However, injection of GMDCs into tumors in Irf8 +32-/- mice did not induce antitumor immunity, consistent with their reported dependence on host cDC1. In contrast, injection of cDC1s into tumors in Irf8 +32-/- mice resulted in their migration to tumor-draining lymph nodes, activation of tumor-specific CD8+ T cells, and rejection of the tumors. Tumor rejection did not require the in vitro loading of cDC1 with antigens, indicating that acquisition of antigens in vivo is sufficient to induce antitumor responses. Finally, cDC1 vaccination showed abscopal effects, with rejection of untreated tumors growing concurrently on the opposite flank. These results suggest that cDC1 may be a useful future avenue to explore for antitumor therapy. See related Spotlight by Hubert et al., p. 918.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.